GSE197112

Development of gene expression signatures for human liver fibrosis

Whole-study status Not suitable

Dataset does not meet the current suitability threshold.

Whole-study downloads — these do not apply your sample requirements.

Selected cohort requirements

Samples meeting selected requirements: 0 cases / 0 controls

View matching samples

4 case / 4 control samples elsewhere in the study have incomplete or conflicting evidence; they are not included above

Patient pairs verified in indexed sample metadata: 0

A case/control comparison meeting these requirements is not confirmed.

Counts describe samples, not independent patients. Pair verification uses explicit subject identifiers in indexed sample metadata. Zero verified pairs does not establish that the study is unpaired; reported matched-normal design alone is insufficient.

Summary

To further development of our gene expression approach to biodosimetry, we have employed whole genome microarray expression profiling as a discovery platform to to study the genes that change in the progress of human liver fibrosis, so as to provide a basis for the clinical treatment of liver fibrosis.

Overall design

Gene expression was detected in 4 patients with liver fibrosis and 4 normal people

Source Evidence

4 sources
Source Contribution Status
GEO

Original dataset metadata, sample metadata, source links, and GEO data availability flags.

Sample records
8 GSM samples
Primary source
recount3

Planned trusted source for processed count availability.

No match found
Expression Atlas

Planned source for curated expression experiment links.

No match found
PubMed

Primary GEO citations and related PubMed articles that mention this dataset.

2 linked publications 2 DOIs

Related publications

  1. Biological aging accelerates hepatic fibrosis: Insights from the NHANES 2017-2020 and genome-wide association study analysis. Annals of hepatology, 2025
  2. Identifying the Crucial Biomarker of MASH-Related HCC. Combinatorial chemistry & high throughput screening, 2025
Available

Metadata Quality Components

Analysis Readiness

Review before analysis
97% DE readiness

Contrast completeness

25/25 pts

Both case and control groups are present in the proposed grouping.

Minimum group size

20/20 pts

Each contrast group has at least 2 samples.

Processed data availability

20/20 pts

Processed data is marked available in the GEO index.

Sample decision clarity

15/15 pts

All samples are assigned to a case or control group.

Blocking warnings

7/10 pts

Warnings are present, but none are critical blockers.

Metadata normalization

10/10 pts

Metadata quality is high enough to support downstream handoff.

Blockers

  • Secondary RNA assay context should be analyzed separately from ordinary bulk RNA-seq.

Next Steps

  • Review blockers and update sample grouping or dataset selection before analysis.

Analysis Preparation Checklist

5/6 ready

Group labels reviewed

Needs review

Siftome proposed case and control labels, but no reviewer confirmation is stored yet.

Open the sample grouping CSV and confirm group labels before analysis.

Minimum sample count met

Ready

Both groups meet the minimum of 2 samples.

Confirm whether the cohort is large enough for the intended statistical analysis.

Processed counts available

Ready

Processed data availability is marked true in the GEO index.

Verify that downloaded processed files contain usable count or expression identifiers.

Ambiguous samples handled

Ready

No review-needed or unassigned samples are present in the proposed grouping.

Review the grouping table for biologically meaningful differences that the automated checks may not detect.

Exclusion decisions recorded

Ready

No hard-excluded samples were detected by the current rules.

Record any manual exclusions in the downstream analysis notes.

Source traceability preserved

Ready

The dataset and sample accessions can be traced back to GEO.

Keep GEO accessions with exported metadata.

Bioinformatician Review

Bioinformatician review required

Ask a bioinformatician to review grouping, count availability, exclusions, and design before DE.

Analysis readiness has blockers that must be resolved before DE.

Assay context may require expert handling before DESeq2-style analysis.

Why This Is Ranked Here

Tumor vs normal
Not suitable Dataset does not meet the current suitability threshold.

Applied Review Decisions

No active review decisions affect this ranking.

Derived Classifications

  • Assay differs from search intent Microarray Search intent expects bulk RNA-seq. Assay came from Normalization rules.
  • Disease context Fibrosis, liver fibrosis Disease context came from Normalization rules.
  • Likely case group Liver fibrosis 4 samples
  • Likely control group Healthy control 4 samples

Intent Interpretation

  • Downgrade or exclusion reason Downgraded assay: microarray cohorts are separated from the RNA-seq intent. Derived from current-intent ranking reasons.

Ranking Facts

Supporting evidence

  • Comparison: Disease/model vs control. Specimen: Biopsy. Comparison suitability: 0%.
  • Interpreted disease metadata: Fibrosis, Liver fibrosis.
  • Processed data is available for downstream review.
  • External evidence: PubMed links 2 publications; 2 DOIs available: PMID 38726780, PMID 39426601.
  • Publication context: Identifying the Crucial Biomarker of MASH-Related HCC.. Combinatorial chemistry & high throughput screening, 2025. PMID 38726780. DOI 10.2174/0113862073287250240424073108.
  • Publication context: Biological aging accelerates hepatic fibrosis: Insights from the NHANES 2017-2020 and genome-wide association study analysis.. Annals of hepatology, 2025. PMID 39426601. DOI 10.1016/j.aohep.2024.101579.

Cautions

  • Downgraded assay: microarray cohorts are separated from the RNA-seq intent.
  • Disease/control design without a tumor/normal comparison is outside tumor/normal triage.
  • Microarray expression context downgraded below primary bulk RNA-seq for the default tissue ranking.
  • Overall score capped because comparison suitability is weak for the selected search intent.
  • Overall score capped because fewer than ten samples limit cohort confidence.
  • Overall score capped because microarray cohorts should be compared separately from RNA-seq cohorts.
  • Comparison suitability score is below the Phase 1 recommended threshold.

Dataset Warnings

Normalized Fields

49 fields

Sample Group Preview

8 rows shown
Show Hide
Study totals: Case 4 | Control 4 | Unassigned 0 | Excluded 0 | Ambiguous 0 8 rows shown
Group Role Accession Title Source / characteristics Reason
Liver fibrosis Case GSM5909318 Fibrosis1 Liver fibrosis people biopsy tissue1 Disease state: Liver fibrosis; Tissue: Liver; Sex: Pooled male and female Case marker detected.
Liver fibrosis Case GSM5909319 Fibrosis2 Liver fibrosis people biopsy tissue2 Disease state: Liver fibrosis; Tissue: Liver; Sex: Pooled male and female Case marker detected.
Liver fibrosis Case GSM5909320 Fibrosis3 Liver fibrosis people biopsy tissue3 Disease state: Liver fibrosis; Tissue: Liver; Sex: Pooled male and female Case marker detected.
Liver fibrosis Case GSM5909321 Fibrosis4 Liver fibrosis people biopsy tissue4 Disease state: Liver fibrosis; Tissue: Liver; Sex: Pooled male and female Case marker detected.
Healthy control Control GSM5909322 Non-fibrosis1 Normal people liver biopsy tissue1 Disease state: Normal; Tissue: Liver; Sex: Pooled male and female Sample-local control marker detected.
Healthy control Control GSM5909323 Non-fibrosis2 Normal people liver biopsy tissue2 Disease state: Normal; Tissue: Liver; Sex: Pooled male and female Sample-local control marker detected.
Healthy control Control GSM5909324 Non-fibrosis3 Normal people liver biopsy tissue3 Disease state: Normal; Tissue: Liver; Sex: Pooled male and female Sample-local control marker detected.
Healthy control Control GSM5909325 Non-fibrosis4 Normal people liver biopsy tissue4 Disease state: Normal; Tissue: Liver; Sex: Pooled male and female Sample-local control marker detected.

Use as Discovery Cohort

External Validation Finder

Carry Siftome's disease, organism, specimen, assay, data type, and accession into a validation project. Uncertain fields remain Unknown.